Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

Publication | Open Access

DOI Full Paper Access

257

Citations

References

2020

Year

Jean van Wyk, Faïza Ajana, Fiona Bisshop, Stéphane De Wit, Olayemi Osiyemi, Joaquín Portilla, Jean‐Pierre Routy, Christoph Wyen, Mounir Ait‐Khaled, Maria Cláudia Nascimento,

Clinical Infectious Diseases

Abstract

References